Quest Diagnostics Incorporated
DGXLast close · Oct 16, 2026235.00−4.15 (−1.74%)
Market cap$25.9B
Of the 85 managers this site tracks, 4 held Quest Diagnostics (DGX) at the end of Q2 2026, their latest 13Fs. The largest position by value was Christopher Davis's, $329.8M; Robert Olstein's ($7.0M) and First Eagle's ($1.6M) follow. No Schedule 13D or 13G is on file for DGX from the activists and large holders the site follows.
Superinvestors holding DGX
| Manager | Firm | Quarter | Shares | Value |
|---|---|---|---|---|
| Christopher Davis | Davis Selected Advisers | Q2 2026 | 2M | $329.8M |
| Robert Olstein | Olstein Capital Management, L.P. | Q1 2026 | 35,800 | $7.0M |
| First Eagle | First Eagle Investment Management, LLC | Q2 2026 | 7,606 | $1.6M |
| Bridgewater | Bridgewater Associates, LP | Q2 2026 | 3,756 | $796,084 |
13D/13G are SEC beneficial-ownership disclosures, triggered only above 5%; a 13F is a quarterly snapshot filed up to 45 days after quarter end. Superinvestor names link to their full portfolios under Investors.